Cor Integrilin confirmatory trial necessary for PTCA approval, committee says.Page 2
COR INTEGRILIN CONFIRMATORY TRIAL NECESSARY FOR APPROVAL of the glycoprotein IIb/IIIa inhibitor, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded at its Feb. 28 meeting. The committee voted 6-2 that the IMPACT-II trial showed positive results for Integrilin as adjunctive therapy in patients undergoing PTCA for prevention of acute cardiac ischemic complications, but members unanimously agreed that the IMPACT-II trial alone is insufficient to show clinical benefit.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth